Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus + Gemcitabine in Pancreatic Cancer
NCT00560963Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2007
- Primary completion
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of everolimus in pancreatic adenocarcinoma (PDAC), sponsored by Novartis. Started Oct 2007; status: completed.
02
Drugs
everolimus
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00560963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00560963.